CONMED Corporation (Nasdaq:CNMD) today announced
financial results for the first quarter ended March 31, 2015.
First Quarter 2015 Financial Highlights
- Sales were $177.9 million, a decrease
of 2.2% compared to the first quarter of 2014. On a constant
currency basis, sales increased 0.8% over the prior-year
period.
- Diluted earnings per share (GAAP) were
$0.23, compared to $0.31 in the first quarter of 2014.
- Adjusted diluted earnings per share
were $0.42 versus $0.49 in the prior-year period.
"Our focus remains on transforming our commercial organization
to facilitate sales and earnings growth. Beyond the positive
constant currency sales growth realized during the quarter, I am
pleased with the operational progress we have made to position our
company for future success," commented Curt R. Hartman, CONMED’s
President and Chief Executive Officer.
Sales Analysis
For the quarter ended March 31, 2015, domestic sales, which
represented 48.9% of total sales, increased slightly due to
positive growth in capital equipment sales. International sales,
which represented 51.1% of total sales, declined 4.2% compared to
the first quarter of 2014 on a reported basis. Foreign currency
exchange rates, including the effects of the FX hedging program,
had a negative impact of $5.5 million on first quarter sales. In
constant currency, international sales increased 1.5% versus the
prior-year period. Outside the United States, an increase in
capital sales was offset by a slight decline in the sales of
single-use products on a constant currency basis.
Earnings Analysis
Reported net earnings of $6.3 million decreased 26.8% in the
quarter, compared to net earnings of $8.6 million in the prior
year. Reported diluted net earnings per share of $0.23 decreased
25.8% in the quarter compared to the prior year. Reported net
earnings include restructuring costs in 2015 and 2014, and charges
for a patent dispute, shareholder activism, and the New York State
corporate tax reform in 2014. The effect of each of these items on
reported net earnings appears in the reconciliation of GAAP to
non-GAAP measures provided below.
Excluding the impact of the items described above, adjusted net
earnings of $11.8 million decreased 13.1% and adjusted diluted net
earnings per share of $0.42 decreased 14.3% year over year. The
benefits of higher sales volume and lower operating expenses in the
current quarter were more than offset by the negative impact of
foreign currency, the expensing of unfavorable production variances
incurred in prior periods, and a higher tax rate.
2015 Outlook
The Company reiterated its previously disclosed constant
currency sales guidance, which calls for organic sales growth in
2015 to be in the range of 1% to 3%. If foreign currency exchange
rates hold near current levels, the Company expects net sales for
the last three quarters of 2015 to be negatively impacted by $3.9
million as compared to prior sales guidance, which was based on
January 23, 2015 currency rates. Using current exchange rates,
CONMED now anticipates that reported sales for 2015 will be in the
range of $723 million to $738 million, representing a range of (2%)
to 0%, and adjusted diluted net earnings per share will be in the
range of $1.82 to $1.92.
Conference Call
The Company’s management will host a conference call today at
4:30 p.m. ET to discuss its first quarter results.
To participate in the conference call, dial 877-280-4961
(domestic), or 857-244-7318 (international), and provide the
passcode “CONMED.”
This conference call will also be webcast and can be accessed
from the Investors section of CONMED's web site at www.conmed.com.
The webcast replay of the call will be available at the same site
approximately one hour after the end of the call.
A recording of the call will also be available from 6:30 p.m. ET
on Wednesday, April 22, 2015, until 11:59 p.m. ET on Wednesday,
April 29, 2015. To hear this recording, you may dial 888-286-8010
(domestic) or 617-801-6888 (international) and enter the passcode
72447655.
About CONMED
CONMED is a medical technology company that provides surgical
devices and equipment for minimally invasive procedures. The
Company’s products are used by surgeons and physicians in a variety
of specialties, including orthopedics, general surgery, gynecology,
neurosurgery and gastroenterology. The Company distributes its
products worldwide from several manufacturing locations. CONMED has
a direct selling presence in 16 countries outside the United States
and international sales constitute over 50% of the Company’s total
sales. Headquartered in Utica, New York, the Company employs 3,400
people. For more information, visit www.conmed.com.
Forward-Looking Statements
This press release contains forward-looking statements based on
certain assumptions and contingencies that involve risks and
uncertainties. The forward-looking statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and relate to the Company's performance on a
going-forward basis. The forward-looking statements in this press
release involve risks and uncertainties which could cause actual
results, performance or trends, to differ materially from those
expressed in the forward-looking statements herein or in previous
disclosures. In addition to general industry and economic
conditions, factors that could cause actual results to differ
materially from those discussed in the forward-looking statements
in this press release include, but are not limited to the risks
relating to forward-looking statements discussed in the Company's
Annual Report on Form 10-K for the fiscal year ended December 31,
2014.
Supplemental Information - Reconciliation of GAAP to Non-GAAP
Financial Measures
We supplement the reporting of our financial information
determined under accounting principles generally accepted in the
United States (GAAP) with certain non-GAAP financial measures,
including percentage sales growth in constant currency; adjusted
gross profit; cost of sales excluding specified items; adjusted
selling and administrative expenses; adjusted operating income;
adjusted effective income tax rate; adjusted net earnings; and
adjusted diluted net earnings per share (EPS). We believe that
these non-GAAP measures provide meaningful information to assist
investors and shareholders in understanding our financial results
and assessing our prospects for future performance. Management
believes percentage sales growth in constant currency and the other
adjusted measures described above are important indicators of our
operations because they exclude items that may not be indicative of
or are unrelated to our core operating results and provide a
baseline for analyzing trends in our underlying businesses.
Further, the presentation of EBITDA is a non-GAAP measurement that
management considers useful for measuring aspects of the Company’s
cash flow. Management uses these non-GAAP financial measures for
reviewing the operating results and analyzing potential future
business trends in connection with our budget process and bases
certain management incentive compensation on these non-GAAP
financial measures.
To measure percentage sales growth in constant currency, we
remove the impact of changes in foreign currency exchange rates
that affect the comparability and trend of sales. To measure
earnings performance on a consistent and comparable basis, we
exclude certain items that affect the comparability of operating
results and the trend of earnings. These adjustments are irregular
in timing, may not be indicative of our past and future performance
and are therefore excluded to allow investors to better understand
underlying operating trends.
Because non-GAAP financial measures are not standardized, it may
not be possible to compare these financial measures with other
companies' non-GAAP financial measures having the same or similar
names. These adjusted financial measures should not be considered
in isolation or as a substitute for reported sales growth, gross
profit, cost of sales, selling and administrative expenses,
operating income, effective income tax rate, net earnings and
diluted net earnings per share, the most directly comparable GAAP
financial measures. These non-GAAP financial measures are an
additional way of viewing aspects of our operations that, when
viewed with our GAAP results and the reconciliations to
corresponding GAAP financial measures below, provide a more
complete understanding of our business. We strongly encourage
investors and shareholders to review our financial statements and
publicly-filed reports in their entirety and not to rely on any
single financial measure.
Consolidated Condensed Statements of Income Three Months
Ended March 2015 and 2014 (in thousands except per share
amounts, unaudited)
2015 2014 Net sales
$ 177,940 $ 181,941 Cost of sales 85,658 79,359 Gross
profit 92,282 102,582 % of sales 51.9% 56.4% Selling
and administrative expense 74,786 78,364 Research and development
expense 6,542 6,910 Income from operations
10,954 17,308 % of sales 6.2% 9.5% Interest expense
1,460 1,461 Income before income taxes 9,494 15,847
Provision for income taxes 3,182 7,221 Net income $
6,312 $ 8,626 Basic EPS $ 0.23 $ 0.32 Diluted EPS $ 0.23 $
0.31 Basic shares 27,573 27,349 Diluted shares 27,820 27,854
Consolidated Condensed Balance
Sheets
(in thousands, unaudited)
March December 2015 2014
Assets: Cash and cash equivalents $ 65,729 $ 66,332 Accounts
receivable, net 128,950 129,287 Inventories 144,199 148,149 Other
current assets 35,188 37,382
Total Current
Assets 374,066 381,150 Property, plant and equipment, net
132,958 133,429 Goodwill 255,748 256,232 Other intangible assets,
net 313,798 316,440 Other assets 11,176 10,943
Total Assets $ 1,087,746 $ 1,098,194
Liabilities
and Shareholders' Equity Current liabilities $ 113,485 $
115,956 Long-term debt, excluding current maturities 257,201
240,201 Other liabilities 142,970 160,739 Shareholders' equity
574,090 581,298
Total Liabilities and
Shareholders' Equity $ 1,087,746 $ 1,098,194
Consolidated Condensed Statements of Cash Flows
Three Months Ended March 2015 and
2014
(in thousands, unaudited)
2015 2014 Operating Activities
Net income $ 6,312 $ 8,626 Depreciation and amortization 10,170
10,868 Changes in operating assets and liabilities and other, net
(1,673) (2,469)
Net cash provided by operating
activities 14,809 17,025
Investing
Activities Payments related to business acquisitions (853) -
Purchases of property, plant, and equipment (4,061)
(4,065)
Net cash used in investing activities (4,914)
(4,065)
Financing Activities Proceeds of debt
17,000 27,000 Payments related to distribution agreement (16,667)
(16,667) Dividend payments on Common Stock (5,510) (5,545)
Repurchase of Common Stock - (16,862) Other, net 543
867
Net cash used in financing activities (4,634) (11,207)
Effect of exchange rate change on cash and cash equivalents
(5,864) 122 Net increase (decrease) in cash and cash
equivalents (603) 1,875 Cash and cash equivalents at beginning of
period 66,332 54,443
Cash and cash equivalents at
end of period $ 65,729 $ 56,318
Sales Summary Three
Months Ended March 2015 and 2014
(in millions, unaudited)
% Change 2015 2014
AsReported
ConstantCurrency
Orthopedic Surgery $ 98.6 $ 105.9 -6.9% -3.2% General
Surgery 66.1 63.5 4.1% 5.8% Surgical Visualization 13.2
12.5 5.6% 9.6% $ 177.9 $ 181.9 -2.2% 0.8% Single-use
products $ 140.1 $ 146.4 -4.3% -1.4% Capital products 37.8
35.5 6.5% 9.9% $ 177.9 $ 181.9 -2.2% 0.8%
Reconciliation of Reported Net Earnings
to Adjusted Earnings
Three Months Ended March 2015 and 2014(in thousands except
per share amounts, unaudited)
2015 Gross
Profit
Selling
&AdministrativeExpense
OperatingIncome
NetIncome
EffectiveTax Rate
DilutedEPS
As reported $ 92,282 $ 74,786 $ 10,954
$ 6,312 33.5% $ 0.23 % of sales 51.9%
6.2%
Restructuring costs1
2,329 (6,180) 8,509
5,445 1.2% 0.19
Adjusted $
94,611 $ 68,606 $ 19,463 $ 11,757 34.7%
$ 0.42 % of sales 53.2% 10.9%
2014 Gross Profit
Selling
&AdministrativeExpense
OperatingIncome
NetIncome
EffectiveTax Rate
DilutedEPS
As reported $ 102,582 $ 78,364 $ 17,308
$ 8,626 45.6% $ 0.31 % of sales 56.4% 9.5%
Restructuring costs1 948 (713) 1,661 1,063 -0.9% 0.04
Patent dispute and shareholder
activism2
- (2,484) 2,484 1,590 -1.1% 0.06
New York State corporate tax reform3
- - - 2,258
-11.3% 0.08
Adjusted $ 103,530 $ 75,167
$ 21,453 $ 13,537 32.3% $ 0.49 % of
sales 56.9% 11.8% 1 In 2014 and 2015, the Company continued
its operational restructuring, including the consolidation of our
Centennial, Colorado manufacturing operations into other existing
CONMED manufacturing facilities. Additionally, in 2014 and 2015,
the Company restructured certain sales, marketing and
administrative functions and incurred severance and other related
costs. 2 In 2014, the Company incurred legal and settlement costs
associated with a patent infringement claim as well as shareholder
activism related costs. 3 In 2014, New York State enacted corporate
tax reform changing the tax rate of a manufacturing company such as
CONMED to essentially 0%. As a result, our previously recorded New
York State net deferred tax assets were written off to income tax
expense.
CONMED Corporation Reconciliation of Reported
Net Income to EBITDA & Adjusted EBITDA Three Months
Ended March 2015 and 2014 (in thousands, unaudited)
2015 2014 Net income $ 6,312 $ 8,626 Provision
for income taxes 3,182 7,221 Interest expense 1,460 1,461
Depreciation 4,633 4,568 Amortization 5,390 6,154
EBITDA $ 20,977 $ 28,030 Stock based compensation
1,256 1,185 Restructuring costs 8,509 1,661 Patent dispute and
shareholder activism - 2,484
Adjusted EBITDA $
30,742 $ 33,360
EBITDA Margin EBITDA 11.8%
15.4% Adjusted EBITDA 17.3% 18.3%
CONMED CorporationLuke PomilioChief Financial
Officer315-624-3202LukePomilio@conmed.com
CONMED (NASDAQ:CNMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
CONMED (NASDAQ:CNMD)
Historical Stock Chart
From Apr 2023 to Apr 2024